| Title | Claps | Level | Year | L/Y |
|---|---|---|---|---|
|
Neurofilament light‐chain response during therapy with antisense oligonucleotide tofersen in SOD1‐related ALS: Treatment experience in clinical practice
19 auth. Thomas Meyer, Peggy Schumann, P. Weydt, S. Petri, Y. Koc, S. Spittel, S. Bernsen, R. Günther, Jochen H Weishaupt, Marie Dreger, ...
In amyotrophic lateral sclerosis (ALS) caused by superoxide dismutase 1 (SOD1) gene mutations (SOD1‐ALS), the antisense oligonucleotide tofersen had been investigated in a phase III study (VALOR) and subsequently introduced in an expanded access pro…
In amyotrophic lateral sclerosis (ALS) caused by superoxide dismutase 1 (SOD1) gene mutations (SOD1‐ALS), the antisense oligonucleotide tofersen had been investigated in a phase III study (VALOR) and subsequently introduced in an expanded access program. In this study we assess neurofilament light chain (NfL) before and during tofersen treatment.
Published in
Muscle and Nerve
|
4
|
5 | 2023 |
Social Media Posts